LevOss
Copenhagen
About LevOss
The most common treatment of bone defects involves the use of autograft suffering from co-morbidity and the need for two operations. Others include allografts and alloplastics, but none have succesfully built longterm functional bone in vivo. Current treatment options for severe articular cartilage injuries are expensive, lengthy, palliative in nature, and result in generation of fibrous cartilage, which is ill adapted to the mechanical forces within a large joint, such as the knee. The LevOss scaffolds for bone and cartilage target a clearly defined market for spinal fusion surgery and for grade III/IV cartilage injuries with an increasing demand for better solutions and few competitors.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Last round: Series Unknown (Jan 2014)
- Website: levoss.com
- Phone: (452)194-7856
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/levoss-1666700 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.